Future oncology (London, England) · 2024
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karacin Cengiz, Sunar Veli, Urakci Zuhat, Yilmaz Ali, Ayhan Murat, Ersoy Mustafa, Guven Deniz Can, Erturk Ismail, Durmus Yasin, Karacin Pinar, Boran Nurettin, Ustun Yaprak Engin, Meydan Mutlu, Dogan Mutlu, Oksuzoğlu Berna, Ates Ozturk, Karaca Mustafa, Uncu Dogan, Ergun Yakup, Arik Zafer
Аннотация
Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.